BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
You may also be interested in...
With the $770m acquisition, Alcon will gain two commercial eye drop products for glaucoma and a Phase III candidate for dry eye.
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.